NewsRoom Articles - Page 71 of 154 - PsychedelicNewsWire (PNW)

TuesdayJan 25, 2022 12:21 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Reports Findings of Commissioned Study Showing a Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment for Select Mental Conditions

The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies…

MondayJan 24, 2022 12:29 pm

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices

Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapy The products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy support The planned launch follows an amendment to federal regulations allowing physicians to request and prescribe restricted drugs for treatment-resistant patients Canada began the year on a high note by updating the Special Access Program (“SAP”), a move that demonstrates the government’s serious consideration of the…

MondayJan 24, 2022 10:49 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) to Launch Specialized Psychedelic Program in Canada

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) announced that it would be launching a special access psychedelic-assisted psychotherapy program, called the Special Access Support and Supply Program. The program will be available to patients who require alternative treatment modalities in Canada. The country recently added psilocybin and MDMA to its Special Access Program. Mydecine’s objective is to change the way in which mental health conditions and addiction disorders are treated. The company will provide support services through the program, which will play an important role in fulfilling the company’s mission statement. This is in addition to offering specialized psychedelic…

FridayJan 21, 2022 10:38 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Corporate Update Points to Profitability in 2022 and Beyond

In 2021, Delic’s investments and acquisitions allowed for an annualized revenue run-rate of over $9MM Going into the new year, the company looks forward to opening additional ketamine infusion treatment clinics, growing them by 15 within the next 18 months Delic’s growth has been attributed to the strong demand for alternatives to current treatments for mental health conditions Its management is confident that the foundations laid down so far position Delic for growth and profitability in 2022 and beyond 2021 was an excellent year for Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), as indicated in the company’s recent update…

FridayJan 21, 2022 10:35 am

Ancient Latin American Empire Could Have Thrived Thanks to Psychedelic-Infused Beer

A new study has found that the leaders of Wari may have laced their beer with hallucinogens to keep their political control for centuries. The drugs are said to have been extracted from plant seeds. The Wari are a South American civilization that ruled the highlands of what is now known as Peru, before the Incas. The culture occupied the highlands between 600 AD and 1000 AD. Archaeological excavations that were conducted between 2013 and 2017 at the Quilcapampa site in the south of Peru have discovered that the tribe used seeds derived from the vilca tree then combined the…

ThursdayJan 20, 2022 10:03 am

Study Finds That Sleep Deprivation Increases Serotonin 2AReceptor Levels in Brain

A new study conducted by researchers at the University of Arizona Health Sciences has found that sleep deprivation can cause a significant increase in serotonin 2A levels in a matter of hours in animal models.Serotonin 2A, or the 5-HT2A receptor, plays a crucial role in cognition, perception and psychosis. The receptor is extensively distributed in the brain and is responsible for the psychedelic effect of substances such as LSD and psilocybin. Abnormal function of 5-HT2A receptors has been linked to psychiatric disorders, including schizophrenia, which explains why antipsychotic medications prescribed for the treatment of schizophrenia have been designed to target…

WednesdayJan 19, 2022 2:21 pm

Canada Achieves New Psychedelic Milestone After Holding First Psilocybin Therapy Group Session

Canada held its first legal psilocybin therapy group session recently. Psilocybin is an active hallucinogenic compound found in magic mushrooms. Various studies conducted by major research institutions have found that psilocybin possesses therapeutic benefits. For instance, studies by Johns Hopkins University, New York University and the University of California Los Angeles have discovered that psilocybin can be used to effectively decrease end-of-life distress in patients with terminal conditions. The session, which was hosted in Vancouver, British Columbia, was facilitated by My Community Journeys, a not-for-profit health-care organization. The therapy session included nine end-of-life patients who had received legal exemptions from…

WednesdayJan 19, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Attended This Year’s H.C. Wainwright Bioconnect Virtual Conference

Delic Holdings Corp is a leader in new medicines and treatments for a modern world, with a business network which includes psychedelic wellness clinics, a licensed psilocybin research lab, a famed psychedelic wellness event, and dedicated media platforms The company announced that its co-founder and CEO, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference on January 10-13, 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has long been known for its role as a trailblazer in improving access to health benefits across the country and reframing the conversation…

WednesdayJan 19, 2022 9:00 am

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast

Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap…

WednesdayJan 19, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year

Company marked host of major milestones and accomplishments in 2021 Approvals, licenses, expansions and growth all essential pieces of Cybin success CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022 As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off big last year, with the company marking a host of major milestones and accomplishments and looking toward more of the same for 2022. "2021 was an exciting year for Cybin,” said Cybin CEO…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000